FDA’s Regulatory Reforms to Unlock Competition and Lower Drug Costs

Key Points

• The aim is to explore FDA's initiatives to facilitate biosimilar approvals and promote their use.
• Discussed regulatory changes by the FDA
• Analyzed criteria for biosimilar approvals
• Examined potential impact on drug pricing and availability
• Removal of burdensome criteria could lead to faster biosimilar approvals
• Encouraging biosimilars over branded drugs may lower treatment costs
• Greater access to biosimilars for patients is anticipated